The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Feature|Articles|July 30, 2026
From hype to practice: Urologists assess AI's real impact
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead, Tracy Ann Politowicz
AI in medicine is here. What happens next matters for the future of health care delivery.
Advertisement
Advertisement
When artificial intelligence (AI) first entered the clinical landscape, its potential painted a promising picture: one where clinicians could spend more time with their patients and less time on routine administrative tasks, helping to improve efficiency, reduce burnout, and bring the joy back to medicine. As these tools become more routine, the question remains: Has AI delivered on its expectations?
Related to this article
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Advertisement
Advertisement